Faraday Pharmaceuticals in Seattle named Stephen Hill, MD, its new CEO, according to The Seattle Times.
Here are three points:
1. Prior to this appointment, Dr. Hill was CEO and president of Targacept. He also worked for Solvay Pharmaceuticals as president and for ArQule as president and CEO.
2. On the board of directors for Catalyst Biosciences, Dr. Hill is also a board member of Cellectar Biosciences and Lipocine.
3. Dr. Hill received his medical degree from the University of Oxford, United Kingdom.